Trial Profile
An open label, non comparative, multicenter clinical trial to observe the efficacy and safety of olmesartan medoxomil and hydrochlorothiazide combined with amlodipine in Chinese patients with mild to moderate essential hypertension, who had insufficient response for amlodipine monotherapy.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2016
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Olmesartan medoxomil (Primary) ; Olmesartan medoxomil/hydrochlorothiazide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 21 May 2012 Planned end date 29 Mar 2013 added as reported by Chinese Clinical Trial Register.
- 06 Mar 2012 New trial record